№ 1 / 2019 / 125-135

DOI 10.15372/SSMJ20190118

THE ROLE OF ENDOTHELIAL DYSFUNCTION AS A PART OF SYSTEMIC INFLAMMATORY RESPONSE IN PATHOGENESIS OF AGGRESSIVE AND INDOLENT NON-HODGKIN’S LYMPHOMAS

Author: Seregina O.B.¹, Babaeva T.N.², Pospelova T.I.³

Abstract

Objective. To study of manifestation of angiogenic and hemostatic forms of endothelial dysfunction and systemic inflammatory response in patients with non-Hodgkin’s lymphomas at the onset of disease. Material and methods. A total of 99 patients were enrolled in this study, including 55 patients with aggressive variants and 44 patients with indolent variants. The average age was 60.71±10.63 years. The serum level of vascular endothelial growth factor (VEGF) was measured as a marker of angiogenic form of endothelial dysfunction, the serum levels of thrombomodulin, D-dimers, soluble fibrin-monomer complex (SFMC) and level of Willebrand factor activity were used for evaluation of hemostatic form of endothelial dysfunction. To assess the degree of systemic inflammation response the serum levels of proinflammatory cytokines – TNF-α, IL-1β, IL-6 were measured, as well as serum level of acute phase proteins – C-reactive protein (CRP), fibrinogen. The serum level of IL-4 was used to evaluate antinflammation resistance. Results and discussion. Proinflammatory cytokine (TNF-α, IL-1β and IL-6) content was higher in both studied groups compare to the control group. Serum concentration of anti-inflammatory cytokine IL-4 in studied groups did not differ from the level in the controls group. CRP and fibrinogen serum content was increased only in group of patients with aggressive variants. There was a significant correlation between the level of CRP and proinflammatory cytokines in aggressive lymphoma group. Serum content of VEGF, thrombomodulin, D-dimers, SFMC and Willebrand factor activity were increased in both studied group in comparison with the control group. Concentration of thrombomodulin, D-dimers, SFMC and Willebrand factor activity was higher in patients with aggressive than in patients with indolent lymphomas. Conclusion. The signs of angiogenic and hemostatic forms of endothelial dysfunction in patients with aggressive and indolent variants of non-Hodgkin’s lymphoma were detected, as well as manifestation of systemic inflammatory response and attenuation of anti-inflammatory resistance with development of cytokines imbalance with proinflammatory cytokines predominance. The manifestations of systemic inflammatory response and hemostatic type of endothelial dysfunction with activation of coagulation were displayed more prominently in the aggressive lymphoma group.

Key words

types of endothelial dysfunction, systemic inflammatory response, non-Hodgkin’s lymphomas, cytokines imbalance, anti-inflammatory resistance

References

Abrosimov V.N., Aristarkhov V.G., Byalovsky Yu.Yu., Weiss I.E. Clinical pathophysiology. Saint-Petersburg: SpetsLit, 2012. 432 p. [In Russian].

Alves B.E., Montalvao S.A.L., Aranha F.J.P., Lorand-Metze I., De Souza C.A., Annichino-Bizzacchi J.M., De Paula E.V. Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. J. Transl. Med. 2011. 9. (1). 23.

Arazi H.C., Doiny D.G., Torcivia R.S., Grancelli H., Waldman S.V., Nojek C., Fornari M.C., Badimon J.J. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. Interact. Cardiovasc. Thorac. Surg. 2010. 10. (6). 863-867.

Barkagan Z.S., Momot A.P. Diagnostics and controlled therapy of hemostatic disorders. Moscow: Newdiamed, 2008. [In Russian].

Boehme M.W., Deng Y., Raeth U., Bierhaus A., Ziegler R., Stremmel W., Nawroth P.P. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology. 1996. 87. (1). 134-140.

Boneu B., Abbal M., Plante J., Bierme R. Factor-VIII complex and endothelial damage. Lancet. 1975. 305. (7922). 1430.

Boneu B., Bes G., Pelzer H., Sie P., Boccalon H. D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis. Thromb. Haemost. 1991. 65. (1). 28-31.

Brown Z., Gerritsen M.E., Carley W.W., Strieter R.M., Kunkel S.L., Westwick J. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells. Differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma. Am. J. Pathol. 1994. 145. (4). 913-921.

Cedervall J., Dimberg A., Olsson A.K. tumor-induced local and systemic impact on blood vessel function. Mediators Inflamm. 2015. 2015. 1-8.

Chernekhovskaya N.E., Shishlo V.K., Chomaeva A.A., Kodina T.V. Endothelium of blood and lymphatic vessels. Moscow: VNII zhivotnovodstva, 2010. 182 p. [In Russian].

Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., Pober J.S., Wick T.M., Konkle B.A., Schwartz B.S., Barnathan E.S., McCrae K.R., Hug B.A., Schmidt A.M., Stern D.M. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998. 91. (10). 3527-3561.

Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.-Z. Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor. J. Biol. Chem. 1996. 271. (2). 736-741.

Demyanov A.V., Kotov A.Yu., Simbirtsev A.S. The diagnostic value of cytokine level study in clinical practice. Tsitokiny i vospalenie = Cytokines and Inflammation. 2003. 2. (3). 20–35.

Dharmasaroja P., Dharmasaroja P.A., Sobhon P. Increased plasma soluble thrombomodulin levels in cardioembolic stroke. Clin. Appl. Thromb. Hemost. 2012. 18. (3). 289-293.

Dirkx A.E.M., oude Egbrink M.G.A., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukocyte Biol. 2006. 80. (6). 1183-1196.

Dolgov V.V., Svirin P.V. Laboratory diagnosis of hemostasis disorders. Tver: Triadа, 2005. 227 p. [In Russian].

Dormond O., Bezzi M., Mariotti A., Ruegg C. Prostaglandin E2 promotes integrin Vβ3-dependent endothelial cell adhesion, Rac-activation, and spreading through cAMP/PKA-dependent signaling. J. Biol. Chem. 2002. 277. (48). 45838-45846.

Duvoix A., Dickens J., Haq I., Mannino D., Miller B., Tal-Singer R., Lomas D.A. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013. 68. (7). 670-676.

Emilie D., Wijdenes J., Gisselbrecht C., Jarrousse B., Billaud E., Blay J.Y., Gabarre J., Gaillard J.P., Brochier J., Raphael M. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood. 1994. 84. (8). 2472-2479.

Erdman L.K., Dhabangi A., Musoke C., Conroy A.L., Hawkes M., Higgins S., Rajwans N., Wolofsky K.T., Streiner D.L., Liles W.C., Cserti-Gazdewich C.M., Kain K.C. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: A retrospective case-control study. PLoS ONE. 2011. 6. (2). e17440.

Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin. Oncol. 2002. 29. (6). 10-14.

Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocri. Rev. 1997. 18. (1). 4-25.

Ferrara N., Keyt B. Vascular endothelial growth factor: Basic biology and clinical implications. EXS. 1997. 79. 209-232.

Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.-M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007. 131. (3). 463-475.

Folkman J. Angiogenesis. Annu. Rev. Med. 2006. 57. (1). 1-18.

Foss H.-d., Araujo I., Demel G., Klotzbach H., Hummel M., Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J. Pathol. 1997. 183. (1). 44-50.

Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999. 340. (6). 448-454.

Gerber H.-P., Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. (Berl). 2002. 81. (1). 20-31.

Gusev E.Yu., Chereshnev V.A. Systemic inflammation: theoretical and methodological approaches to the description of the general pathological process model. Part 1. General characteristics of the process. Patologicheskaya fiziologiya i eksperimental'naya terapiya = Pathological physiology and experimental therapy. 2012. (4). 3-14. [In Russian].

Hwa C., Aird W.C. The history of the capillary wall: doctors, discoveries, and debates. Am. J. Physiol. Heart Circ. Physiol. 2007. 293. (5). H2667-H2679.

Kadowaki I., Ichinohasama R., Harigae H., Ishizawa K., Okitsu Y., Kameoka J., Sasaki T. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br. J. Haematol. 2005. 130. (6). 869-877.

Kato H., Kinoshita T., Suzuki S., Nagasaka T., Hatano S., Murate T., Saito H., Hotta T. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma. 1998. 29. (1-2). 71-79.

Klein B., Wijdenes J., Zhang X.G., Jourdan M., Boiron J.M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia // Blood. 1991. 78. (5). 1198-1204.

Kokame K., Zheng X., Sadler J.E. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J. Biol. Chem. 1998. 273. (20). 12135-12139.

Krishnaswamy G., Kelley J., Yerra L., Smith J.K., Chi D.S. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J. Interferon Cytokine Res. 1999. 19. (2). 91-104.

Kuby J. Role of cytokines in the inflammatory response. Immunology, 2^nd edition. Ed. J. Kuby. N.Y.: W.H. Freeman and Company. 313–315.

Lin S.-M., Wang Y.-M., Lin H.-C., Lee K.-Y., Huang C.-D., Liu C.-Y., Wang C.-H., Kuo H.-P. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit. Care Med. 2008. 36. (3). 683-689.

Liu Z.H., Wei R., Wu Y.P., Lisman T., Wang Z.X., Han J.J., Ren D.L., Chen B., Xia Z.L., Zhu Z., Zhang Y., Cui X., Hu H.T., de Groot P.G., Xu W.B. Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. Biomed Environ Sci. 2005. 18. (4). 260-264.

Maroeska te Loo D., Bosma N., van Hinsbergh V., Span P., de Waal R., Clarijs R., Sweep C., Monnens L., van den Heuvel L. Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS. Pediatr. Nephrol. 2004. 19. (7). 754-760.

Martin F.A., Murphy R.P., Cummins P.M. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am. J. Physiol. Heart Circ. Physiol. 2013. 304. (12). H1585-H1597.

Mok C.C., Poon W.L., Lai J.P.S., Wong C.K., Chiu S.M., Lun S.W.M., Ko G.T.C., Lam C.W.K., Lam C.S. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand. J. Rheumatol. 2010. 39. (1). 42-49.

Niitsu N., Okamoto M., Nakamine H., Yoshino T., Tamaru J.-i., Nakamura S., Higashihara M., Hirano M. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur. J. Haematol. 2002. 68. (2). 91-100.

Nilsen E.M., Johansen F.E., Jahnsen F.L., Lundin K.E.A., Scholz T., Brandtzaeg P., Haraldsen G. Cytokine profiles of cultured microvascular endothelial cells from the human intestine. Gut. 1998. 42. (5). 635-642.

Page A.V., Liles W.C. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence. 2013. 4. (6). 507-516.

Papayan L.P., Knyazeva E.S. D-dimer in clinical practice: A handbook for physicians. Moscow: Insayt poligrafika, 2002. 20 p. [In Russian].

Pawlak K., Mysliwiec M., Pawlak D. Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas - the new putative determinants of endothelial dysfunction in haemodialysis patients. Thromb. Res. 2010. 126. (5). 393-398.

Pedersen L.M., Jurgensen G.W., Johnsen H.E. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2005. 128. (6). 813-819.

Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 1997. 150. (3). 815-821.

Petrishchev N.N., Vasina L.V., Vlasov T.D. Typical forms of endothelium dysfunction. Kliniko-laboratornyy konsilium = Clinical and laboratory consultation. 2007. (18). 31-36. [In Russian].

Petrishchev N.N., Vlasov Т.D. Physiology and pathophysiology of the endothelium. Endothelial dysfunction. Causes, mechanisms, pharmacological correction. Ed. N.N. Petrishchev. Saint-Petersburg, 2003. 184 p. [In Russian].

Righini M., Perrier A., De Moerloose P., Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later. J. Thromb. Haemost. 2008. 6. (7). 1059-1071.

Riihijarvi S., Nurmi H., Holte H., Bjorkholm M., Fluge O., Pedersen L.M., Rydstrom K., Jerkeman M., Eriksson M., Leppa S. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. Eur. J. Haematol. 2012. 89. (5). 395-402.

Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 2001. 114. (Pt. 5). 853-865.

Rousseau A., Favier R., Van Dreden P. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: New and useful markers for pre-eclampsia?. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009. 146. (1). 46-49.

Roy L.D., Ghosh S., Pathangey L.B., Tinder T.L., Gruber H.E., Mukherjee P. Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer. 2011. 11. (1).

Sathupan P., Khongphattanayothin A., Srisai J., Srikaew K., Poovorawan Y. The role of vascular endothelial growth factor leading to vascular leakage in children with dengue virus infection. Ann. Trop. Paediatr. 2007. 27. (3). 179-184.

Shapiro N.I., Yano K., Okada H., Fischer C., Howell M., Spokes K.C., Ngo L., Angus D.C., Aird W.C. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock. 2008. 29. (4). 452-457.

Taylan A., Sari I., Kozaci D.L., Yildiz Y., Bilge S., Coker I., Maltas S., Gunay N., Akkoc N. Evaluation of various endothelial biomarkers in ankylosing spondylitis. Clin. Rheumatol. 2011. 31. (1). 23-28.

Triggle C.R., Ding H. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. J. Am. Soc. Hypertens. 2010. 4. (3). 102-115.

Urban M., Wojtkielewicz K., Glowinska B., Peczynska J. Soluble thrombomodulin--a molecular marker of endothelial cell injury in children and adolescents with obesity. Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego: organ Polskiego Towarzystwa Endokrynologow Dzieciecych = Endocrinology, diabetology and metabolic diseases of the developmental age: organ of the Polish Society of Endocrinologists. 2005. 11. (2).73-77. [In Polish].

Walker T.S., Brown J.S., Hoover C.S., Morgan D.A. Endothelial Prostaglandin Secretion: Effects of Typhus Rickettsiae. J. Infect. Dis. 1990. 162. (5). 1136-1136.

Zhao W.-L., Mourah S., Mounier N., Leboeuf C., Daneshpouy M.E., Legres L., Meignin V., Oksenhendler E., Maignin C.L., Calvo F., Briere J., Gisselbrecht C., Janin A. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab. Invest. 2004. 84. (11). 1512-1519.

About Authors (Correspondence):

Seregina O.B. – assistant professor of the department of therapy, hematology and transfusiology, e-mail: alepu@yandex.ru

Full Text

snmzh_1-2019_seregina_125-135.pdf

Received: 27/02/2019

Accepted: 27/02/2019